Related references
Note: Only part of the references are listed.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
H. Avet-Loiseau et al.
LEUKEMIA (2013)
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Herve Avet-Loiseau et al.
BLOOD (2011)
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Kevin D. Boyd et al.
CLINICAL CANCER RESEARCH (2011)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications
Paola E. Leone et al.
CLINICAL CANCER RESEARCH (2008)
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Matthew W. Jenner et al.
BLOOD (2007)
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
Muzaffar H. Qazilbash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
Wee J. Chng et al.
CANCER RESEARCH (2007)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
P Moreau et al.
BLOOD (2002)
Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
T Facon et al.
BLOOD (2001)
Share Paper
